OncoLink at ASCO 2001: Sunday, May 13 | Oncolink

Oncolink Features

Find My Cancer Drug

A Multicenter, Randomized, Double Blind, Placebo (PB) Controlled Trial of Marimastat (MT) In Patients with Glioblastoma Multiforme (GBM) or Gliosarcoma (GS) Following Completion of Conventional, First-Line Treatment Presenter: S. Phuphanich Affiliation: The Marimastat Glioblastoma Study Group Background: The standard adjuvant therapy for GBM is radiation therapy with or without BCNU. The outcomes of therapy for GBM or GS are poor. There is clearly a need...
A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study Of Novel Erythropoiesis Stimulating Protein (NESP) In Patients Undergoing Platinum Treatment For Lung Cancer Presenter: Robert Pirker Affiliation: NESP 980297 Study Group Background: Studies indicate that the carbohydrate content of erythropoietin influences serum half-life. The novel erythropoiesis stimulating protein darbepoetin alfa (NESP) is a...
A phase I and Pharmacologic trial of weekly epothilone B in patients with advanced malignancies Presenter: E.H.Rubin Affiliation: The Cancer Institute of New Jersey, New Brunswick, NJ Background: The epothilones are equipotent and exhibit kinetics similar to taxol in inducing tubulin polymerization into microtubules in vitro and in...
A Phase I study of oxaliplatin in cancer patients with impaired renal function Presenter: M.A. Graham Affiliation: University of Texas Health Science Center, San Antonio Background: Oxaliplatin is a new platinum derivative with activity in several solid tumors, especially in some cisplatin/carboplatin-refractory neoplasms....
A Phase III Study Of Concomitant Oral Pilocarpine To Reduce Hypo-Salivation And Mucositis Assocated With Curative Radiation Therapy (RT) In Head And Neck (H&N) Cancer Patients. RTOG 9709 Presenter: Charles W. Scarantino/Charles B. Scott Affiliation: Multi-institutional Background: Radiotherapy plays a major role in the management of H&N cancer. The major treatment side effects are mucositis and xerostomia (dry mouth), which can...
Accelerated chemoradiation to 70.6 gy is more effective than accelerated radiation to 77.6 gy alone — two year's results of a German multicenter randomized trial (ARO 95-6) Presenter: Volker Gustav Budach Affiliation: Charite University Clinics, Berlin, Germany Background: This study attempts to answer whether accelerated chemoradiation is more effective than accelerated radiation therapy alone? Materials and...
Clinical pharmacology of paclitaxel in relation of patient age: CALGB 9762 Presenter: S.M. Lichtman Affiliation: CALGB, Chicago, IL Background: The taxanes are one of the most important new classes of anticancer agents to emerge in the last decade. Paclitaxel, one of the two taxanes, has been widely used in patients...
Efficacy And Safety Of The Anti-Epidermal Growth Factor Antibody (EGFR) IMC-C225, In Combination With Cisplatin In Patients With Recurrent Squamous Cell Carcinoma Of The Head And Neck (SCCHN) Refractory To Cisplatin Containing Chemotherapy Presenter: Waun Ki Hong/Roy S. Herbst Affiliation: Anderson Cancer Center Background: Patients with recurrent SCCHN who fail to respond to platinum-based therapy rarely respond to second-line treatment This study was performed to evaluate...
Maximizing Local Control And Organ Preservation In Advanced Squamous Cell Head And Neck Cancer (SCHNC) With Hyperfractionated Radiation (HRT) And Concurrent Chemotherapy Presenter: David J. Adelstein Affiliation: Cleveland Clinic Foundation, Cleveland, OH. Background: 5Fu and cDDP are the best studied and most effective drugs for head and neck cancer. Both agents are radiosensitizers. Altered fractionation...
Nutrition and Cancer: An Update What definite positive associations have researchers found between certain nutrients or dietary components and the development of cancer? Very few, according to three researchers who attempted to summarize the state of nutritional research at...
Phase I evaluation of an epothilone B analog (BMS-247550): clinical findings and molecular correlates Presenter: S. Mani Affiliation: NYU Medical Center, NY Background: The epothilones are naturally occurring antimitotic drugs that share with the taxanes a similar mechanism of action without apparent structural similarity. Some early...
Phase III Study Comparing Cisplatin (C) & 5-Flurouracil (F) Versus Cisplatin & Paclitaxel (T) In Metastatic/Recurrent Head & Neck Cancer (MHNC) Presenter: B Murphy Affiliation: Vanderbilt-Ingram Cancer Center Background: CF is the standard combination regimen for MHNC. With expected response rate of 30%, medium survival (MS) 6 mos, 1 yr overal survival (OS) of 20%. An ECOG trial found...
Phase III Trial of BCNU Plus Cisplatin (CDDP) Versus BCNU Alone, and Standard Radiation Therapy (SRT) Versus Accelerated Radiation Therapy (ART) in Glioblastoma (GBM) Patients: NCCTG/SWOG Results Presenter: J.C. Buckner Affiliation: Mayo Clinic, Rochester, MN Background: The adjuvant treatment for GBM is radiation therapy plus or minus BCNU. With this therapy, the median survival is about 10 months and the 5- year overall survival is...
Predicting Risk Of Neutropenic Complications: A Point-Of-Care Assessment Tool Presenter: Lloyd Lininger Affiliation: SUNY Albany, Albany, NY Background: Neutropenia induced by chemotherapy (CT) is associated with increased morbidity and decreased quality-of-life. Dose reductions and delays due to severe neutropenia may...
Preliminary results of RTOG 9703 - a phase II randomized trial of concurrent radiation (RT) and chemotherapy for advanced Squamous Cell Carcinomas (SCC) of the head and neck Presenter: A.S. Garden Affiliation: U.T.M.D. Anderson Cancer Center, Houston, TX Background: Concurrent chemoradiation may improve Survival for advanced Head and Neck cancer. 2. Numerous studies have evaluated different treatment approaches...
Primary Chemotherapy (PCT) For Patients With Operable Oral Cavity Cancer: Results Of A Randomized Study Presenter: Lisa Licitra Affiliation: Istituto Nazionale Tumori, Milan, Italy Background: This study was designed to investigate the impact of neoadjuvant chemotherapy on primary surgery in operable oral cavity cancer. Materials and Methods:...
Role of body-surface area in Cisplatin pharmacokinetics Presenter: F. de Jongh Affiliation: Rotterdam Cancer Institute, Rotterdam, Netherlands Background: Dosages of anticancer drugs are usually calculated on the basis of a uniform standard, the body surface area (BSA). Although many physiological...
Role of body-surface area in Cisplatin pharmacokinetics Presenter: F. de Jongh Affiliation: Rotterdam Cancer Institute, Rotterdam, Netherlands Background: Dosages of anticancer drugs are usually calculated on the basis of a uniform standard, the body surface area (BSA). Although many physiological...
The Shape of Things to Come: Sunday Afternoon Special Session Focuses on the Biology of Cancer During a panel presentation that ASCO members "are likely to be talking about ten years from now," to use the words of ASCO president- elect Dr. Larry Norton, four leading researchers in the molecular biology of cancer looked back, looked...